Amneal Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
400 Crossing Blvd Fl 3, Bridgewater, New...Phone Number
(908) 947-3120Website
www.amneal.comRevenue
$3.1 BillionStock Symbol
AMRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
2
1
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomesRead more
Amneal Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amneal Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Amneal Pharmaceuticals recently announced quarterly report
Amneal Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Amneal Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Amneal Pharmaceuticals launches new products
Check out if Amneal Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Amneal Pharmaceuticals has new funding data
Click to see if Amneal Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Amneal Pharmaceuticals
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Amneal Pharmaceuticals
Compare insights from companies similar to Amneal Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Amneal Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amneal Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amneal Pharmaceuticals.
Amneal Pharmaceuticals financials insights
Gather financial insights about Amneal Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Debt
$250M
Amneal Pharmaceuticals Tech Stack
A closer look at the technologies used by Amneal Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Hiring Plans
Hiring Plans
Amneal Pharmaceuticals News & Media
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDTCompany ParticipantsAnthony DiMeo - Head/VP of Investor RelationsChirag...Amneal Reports Second Quarter 2026 Financial Results
– Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost –Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that it has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, as well as 300 mg iodine/mL in 50 mL vial. Amneal plans to launch these products in the third quarter of 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Amneal Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-dr... Read More
